Performance

The Performance platform is built for the second step of laboratory work: molecules whose activity, stability and reproducibility profile is already documented well enough that the researcher does not need to validate the molecule itself before each experiment. These are the peptides academic industry requests for repeated assays, batch-to-batch comparisons and studies where the variable under study is NOT the peptide but another component of the system.

In 2026 that demand is concentrated in very well-defined families. Growth-hormone secretagogues (CJC-1295, sermorelin, ipamorelin, hexarelin) still lead volume in somatotropic-axis studies. Melanocortin analogs (PT-141 / Melanotan II) are systematically requested in sexual-behavior and thermoregulation research in animal models. Insulin-mimetic fragments and ergogenic peptides under comparative study round out the picture. The usage pattern has shifted from five years ago: labs consume LESS volume per individual experiment but request HIGHER order frequency and greater delivery predictability. It's a market that rewards consistency.

The Performance platform is being assembled to fit that pattern: larger batches with a single analytical reference across runs, lyophilized formulation stable at controlled temperature (-20 °C) for ≥24 months, and a presentation that allows sub-fractionation without measurable potency loss. It is not an available product — it is a line we are closing on QA and traceability before opening it to order.